Trial Profile
Prospective randomized study of safety outcomes treated with edoxaban in patients with stable coronary artery disease and atrial fibrillation
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 04 May 2020
Price :
$35
*
At a glance
- Drugs Edoxaban (Primary) ; Clopidogrel
- Indications Coronary artery disease; Embolism and thrombosis
- Focus Adverse reactions
- Acronyms PRAEDO AF study
- 01 May 2020 Status changed from not yet recruiting to discontinued.
- 04 Apr 2018 New trial record